ABVC BioPharma, Inc. Reports Strong Q2 2024 Financial Results and Strategic Achievements
15 août 2024 07h30 HE
|
ABVC BioPharma, Inc.
• Executed Global Licensing Agreements that could provide up to $292 million in income • Received Cash Milestone Incomes of $116,000 • Achieved Significant Improvements in Earnings •...
ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M
17 avr. 2024 09h00 HE
|
ABVC BioPharma, Inc.
FREMONT, CA, April 17, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in...
ABVC BioPharma Receives U.S. Patent for ADHD Treatment, a $32 Billion Market
21 nov. 2023 08h30 HE
|
ABVC BioPharma, Inc.
FREMONT, CA, Nov. 21, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in...
ABVC BioPharma Receives Taiwanese Patent for Its Treatment of Major Depressive Disorder (MDD)
09 oct. 2023 08h30 HE
|
ABVC BioPharma, Inc.
The Company Holds a US Patent for the Same Treatment FREMONT, CA, Oct. 09, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage...
ABVC BioPharma Regains Compliance With Nasdaq's Minimum Bid Price Requirement
10 août 2023 08h30 HE
|
ABVC BioPharma, Inc.
FREMONT, CA, Aug. 10, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in...
ABVC BioPharma Announces Closing on $1.75 Million Registered Direct Offering
31 juil. 2023 09h30 HE
|
ABVC BioPharma, Inc.
FREMONT, CA, July 31, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in...
ABVC BioPharma Announces Pricing of $1.75 Million Registered Direct Offering
27 juil. 2023 09h22 HE
|
ABVC BioPharma, Inc.
FREMONT, CA, July 27, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in...
ABVC BioPharma Subsidiary BioKey Projects $1.0 Million Proceeds From Dietary Supplement Production
20 juin 2023 08h30 HE
|
ABVC BioPharma, Inc.
FREMONT, CA, June 20, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company specializing in therapeutic solutions in...
ABVC BioPharma Vitargus® Phase II Study Received Ethical Approval at Sydney Eye Hospital in Australia
22 mai 2023 08h30 HE
|
ABVC BioPharma, Inc.
FREMONT, CA, May 22, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in...
ABVC BioPharma Receives US Patent Certificate of PDC-1421 for the Treatment of Major Depressive Disorder
04 mai 2023 08h30 HE
|
ABVC BioPharma, Inc.
FREMONT, CA, May 04, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...